Background: Mycolactones are a family of polyketide-derived macrolide exotoxins produced by Mycobacterium ulcerans, the causative agent of the chronic necrotizing skin disease Buruli ulcer. The toxin is synthesized by polyketide synthases encoded by the virulence plasmid pMUM. The apoptotic, necrotic and immunosuppressive properties of mycolactones play a central role in the pathogenesis of M. ulcerans.

Methodology/Principal Findings: We have synthesized and tested a series of mycolactone derivatives to conduct structure-activity relationship studies. Flow cytometry, fluorescence microscopy and Alamar Blue-based metabolic assays were used to assess activities of mycolactones on the murine L929 fibroblast cell line. Modifications of the C-linked upper side chain (comprising C12–C20) caused less pronounced changes in cytotoxicity than modifications in the lower C5-O-linked polyunsaturated acyl side chain. A derivative with a truncated lower side chain was unique in having strong inhibitory effects on fibroblast metabolism and cell proliferation at non-cytotoxic concentrations. We also tested whether mycolactones have antimicrobial activity and found no activity against representatives of Gram-positive (Streptococcus pneumoniae) or Gram-negative bacteria (Neisseria meningitis and Escherichia coli), the fungus Saccharomyces cerevisiae or the amoeba Dictyostelium discoideum.

Conclusion: Highly defined synthetic compounds allowed to unambiguously compare biological activities of mycolactones expressed by different M. ulcerans lineages and may help identifying target structures and triggering pathways.

Introduction

The macrolide exotoxin mycolactone is a key virulence factor of M. ulcerans and plays a central role in the pathogenesis of Buruli ulcer [1]. Mycolactones have been shown to act both in vivo and in vitro on various mammalian cell types, including fibroblasts [1–6], adipocytes [7], keratinocytes [8], myocytes [9,10], macrophages [2,6,11–14], dendritic cells [15] and T-cells [16–18]. Effects caused by mycolactones include induction of apoptosis/necrosis, cytoskeletal rearrangements, impaired cytokine production and interference with cellular signaling.

The polyketide synthases required for mycolactone biosynthesis are encoded on the extrachromosomal plasmid pMUM [19,20]. M. ulcerans has evolved from a common M. marinum ancestor by acquisition of this plasmid and has subsequently diverged into two principal mycolactone-producing lineages [21,22]. The “classical” lineage includes M. ulcerans isolates associated with Buruli ulcer from Africa and Australia. The “ancestral” lineage includes both Buruli ulcer isolates from Japan, China and Mexico and isolates from fish and frogs previously also designated M. pseudoshottsii, M. iflandii or M. marinum [23,24]. Mycolactones are composed of a 12-membered macrolide core and two attached side chains; a short upper, C-linked side chain (comprising C12–C20) and a longer lower, C5-O-linked polyunsaturated acyl side chain. While the macrolide core structure and upper side chain are conserved, mycolactone populations from different M. ulcerans sub-lineages vary in the length, the number and localization of hydroxyl groups and in the number of double bonds of the lower side chain. M. ulcerans strains may produce several molecular variants of mycolactone, with one or more species dominating [25]. The mycolactone repertoire seems to be highly conserved within a defined geographical sub-lineage of M. ulcerans [25]. Mycolactone A/B is produced by strains of the classical M. ulcerans lineage found in Africa and is regarded as the most potent toxin. Australian classical lineage strains produce - in addition to mycolactone A/B - mycolactone C, which lacks one hydroxyl group. Mycolactone D with an additional methyl group is produced by Chinese strains belonging to the ancestral lineage. M. ulcerans ancestral lineage isolates from fish and frogs have been found to produce the mycolactone variants E and F.

Mycolactones have previously been prepared from M. ulcerans cultures by a two-step extraction procedure, yielding preparations...
of acetone soluble lipids predominantly containing mycolactone. These extracts can be further purified by chromatographic methods [26]; nevertheless, the use of extracted mycolactones for comparative studies may be compromised by the heterogeneity of preparations. Therefore, biological studies with highly defined synthetic mycolactones represent an attractive alternative. Based on the established synthesis of the mycolactone core [27–30], different synthesis strategies have been pursued for the stereoselective partial and total synthesis of mycolactones [31–33]. In addition, simplified C8-desmethyl-mycolactone analogues have been synthesized, which were analyzed for their cytopathic potency by using cell rounding as a parameter to compare cytotoxic activities [34]. No systematic structure-activity relationship studies on larger sets of synthetic mycolactones have been published so far. Results of individual studies cannot be reliably compared, since different readouts, such as cell rounding [22,34,35], cytokine production [36] or flow cytometric parameters [35,36] have been employed. Furthermore, different cell lines (such as Jurkat T-cells [36], murine fibroblasts [22,34,35] and sets of human tumor cell lines [37] have been used and cytotoxic activity has been assessed after different times, such as 24 hours [36] or 24 and 48 hours [35]. Most of these structure-activity studies have been limited to mycolactone A/B and a limited number of derivatives. A comparison of the activity of eight C8-desmethyl-mycolactone analogues is hampered by the fact that lack of the C8-methyl substituent reduces the cytopathic activity by a factor of 125 [34]. Here, we have performed more systematic comparative studies using synthetically produced natural toxins and additional structural mycolactone variants that are not found in nature.

Materials and Methods

Synthetic mycolactones

We recently reported the synthesis of mycolactone A/B [38]. Details of the syntheses of mycolactones C and F and of the six non-natural mycolactone derivatives will be published elsewhere (Gersbach et al., manuscript in preparation). Briefly, all mycolactones discussed here were prepared by the same overall strategy that we had previously developed for the synthesis of mycolactone A/B. Thus, a modified Suzuki coupling was employed to establish the C12–C13 bond and elaborate the full upper side chain and a Yamaguchi type acylation reaction was used to attach the lower side chain. All final products used for biological testing were purified by RP-HPLC; they were generally obtained as mixtures of (interconverting) double bond isomers. Analytical data for the synthetic compounds are provided as supplementary information (S1).

For biological testing, 0.5 mg/ml stock solutions of the mycolactones were prepared in cell culture grade DMSO (Sigma). Stock solutions were aliquoted and stored frozen at −20°C.

Cytotoxicity assay

Murine L929 fibroblasts were grown in RPMI medium (Gibco) supplemented with 10% FCS (Sigma), 2 mM glutamine (Gibco) and 0.05 mM β-mercaptoethanol (Gibco) and incubated at 37°C and 5% CO2. Cells were passaged 3–6 times prior to use in cytotoxicity experiments. For flow cytometry analysis 24,000 cells were seeded into 24-well plates (Falcon) and allowed to adhere 1–2 h. After incubation for 24, 48 or 72 h, cells were detached from the culture plates by repeated gentle flushing through a pipette tip without use of Trypsin-EDTA. Harvested cells were centrifuged for 10 min at 1,200xg, resuspended in 300 µl binding buffer with 0.2 µg/ml Annexin V-FITC (Annexin V kit, Calbiochem) and incubated for 30 min at 4°C. The cells were spun again and pellets were resuspended in 300 µl staining buffer containing 0.3 µg/ml propidium iodide (AnnexinV kit, Calbiochem). Cell suspensions were analyzed by flow cytometry using a BD FACS Calibur Flow Cytometer (Becton Dickinson) and apoptotic (A+/PI−) and necrotic (A+/PI+) cell populations were determined using the CellQuest Pro Software (Becton Dickinson). The experiments were set up in triplicates and performed at least twice. Mycolactone A/B in a concentration range of 3.75 to 120 ng/ml was included as control in all experiments. The mycolactone concentration at which 50% of the cells were killed (LC50) was determined by plotting the percentage of affected cells (sum of A+/PI− and A+/PI+) against the log concentration of the individual mycolactones. In Fig. 1–3 only data for concentrations close to the LC50 are shown.

Inhibition of cell proliferation

To measure proliferation of L929 fibroblasts, 24,000 cells were seeded into 24-well plates (Falcon) and allowed to adhere 1–2 h. The medium was aspirated and replaced by 500 µl medium containing 60 ng/ml of mycolactone and 0.06% DMSO (v/v). At time point 0 and after 24, 48 and 72 h fibroblasts were harvested, diluted 1:100 in isotonous solution and measured using an automated cell counting device (CasyTT, Schärfe System). The experiment was set up in triplicates and performed twice.

Microscopic analysis

24,000 cells were seeded on four-chamber glass slides (BD Falcon) with complete RPMI medium and allowed to adhere for 24 hours. The medium was aspirated and replaced by 500 µl medium containing different concentrations of mycolactone. After the specified incubation period, cells were washed once in PBS and fixed with 4% formaldehyde (Medite) for 20 min. Fibroblasts were washed again in PBS prior to permeabilization in Triton X-100 (0.1% in PBS) for 20 min. Cells were rinsed in PBS and blocked by incubation in 4% FBS in PBS for additional 20 min. The actin cytoskeleton was stained by incubating the cells for 1 h at room temperature with Texas Red-X phalloidin (3 units/ml, in blocking solution, Molecular Probes). Cells were washed in blocking buffer, then in PBS. ProLong Gold antifade reagent (Invitrogen)

Author Summary

Buruli ulcer is a chronic necrotizing skin disease caused by Mycobacterium ulcerans. The characteristic histopathological features of Buruli ulcer, severe destruction of subcutaneous tissue with minimal inflammation in the core of the lesion, are primarily attributed to the cytopathic activity of mycolactone, the macrolide exotoxin of M. ulcerans. Different geographical lineages of M. ulcerans produce different structural variants of mycolactone. By using highly defined synthetic mycolactones, including both naturally occurring molecular species and additional non-natural variants, we have assessed the influence of the structure of the C-linked upper side chain and the lower C5-O-linked polyunsaturated acyl side chain on biological activity. Changes in the lower side chain affected the cytopathic activity against mammalian cells more profoundly than changes in the upper side chain. Mycolactone A/B had no antimicrobial activity against Gram-positive and Gram-negative bacteria and was also inactive against Saccharomyces and Dictyostelium.
containing diaminido-2-phenylindole (DAPI) was used for nuclear counterstaining. Cover slips were mounted onto the slides and cell rounding as well as the staining of nuclei and actin cytoskeleton was qualitatively analyzed by fluorescence microscopy (Leica DM 5000 B). Mycolactone-induced changes in the pattern and intensity of the Texas Red-X phalloidin staining of the cytosolic actin cytoskeleton as well as in the uniform, round and clear-edged DAPI staining of nuclei in healthy cells were observed.

Alamar Blue – based analysis of metabolic activity

Metabolic activity of mycolactone-treated L929 fibroblasts was analyzed by performing Alamar Blue assays. Seeding of cells and
addition of mycolactones were performed as described for the flow cytometry-based cytotoxicity assays. After mycolactone treatment, alamarBlue® reagent (Invitrogen) was added to the wells (10% v/v) and the cells were further incubated for 1 hour at 37°C and 5% CO₂. Fluorescence intensities were measured using a SpectraMax Gemini XS (Molecular Devices) and the values were calculated referring to the DMSO control (0 ng/ml mycolactone) set at 100%. The experiments were set up in triplicates and performed at least twice. The concentration at which the metabolic activity of cells was inhibited by half (IC₅₀) was determined by plotting the fluorescence intensity against the log concentration of the individual mycolactones.

Assessment of the antimicrobial activity of mycolactone A/B

Antimicrobial activity of mycolactone on Streptococcus pneumoniae (SP1, P1577), E. coli (DE3) and Saccharomyces cerevisiae was tested by applying the disk agar diffusion (Kirby-Bauer) method. Bacteria were pelleted, resuspended in PBS and spread on blood agar/LB agar. The plates were dried for 30 min and sterile paper disks were distributed circle-like onto the agar. Mycolactone A/B solutions of different concentrations (0.003 µg/ml to 10 µg/ml) were applied on the paper disks (40 µl). The agar plates were incubated o/n at 37°C and then analyzed for potential zones of inhibition.

The effect of mycolactone A/B on the growth of Dictyostelium discoideum DH1-10 was assessed by performing an Alamar Blue assay in a 24-well format. 2,000 cells were seeded in 500 µl medium containing mycolactone in the concentration range of 0.16 to 500 ng/ml. As controls, DMSO and blasticidin were used. After an incubation period of 3 days at room temperature, alamarBlue® reagent (Invitrogen) was added and the plate was further incubated for 18 hours at room temperature.

Results

Recently we described a novel strategy for the synthesis of mycolactone A/B that is based on the stereoselective construction of the macrolactone core by ring-closing olefin metathesis and subsequent incorporation of the C- and O-linked side chains by suitable fragment couplings [38]. Taking this synthesis approach a set of natural mycolactones (mycolactone A/B, mycolactone C, mycolactone F) and additional derivatives displaying modifications...
in the lower or upper side chain (PG-119, PG-120, PG-155, PG-157, PG-165 and PG-182) were produced (see Figures 1, 2 and 3) for biological testing. The biological activity of these synthetic compounds on the murine L929 fibroblast cell line was assessed by flow cytometry. After treatment with different concentrations of synthetic mycolactones, cells were stained both with FITC-labeled annexin-V and with propidium iodide. Annexin-V binds to exposed phosphatidylserine residues translocated from the inner to the outer leaflet of the plasma membrane in cells undergoing apoptosis. Propidium iodide intercalates into the DNA of cells that have lost nuclear membrane integrity, serving as a marker for necrosis. Quadrant analysis was performed to determine apoptotic (A<sup>+</sup>+PI<sup>2</sup>) and necrotic (A<sup>+</sup>+PI<sup>+</sup>) cell populations.

While first signs of mycolactone A/B-mediated cell death were already detectable after 24 hours, significant effects were only observed after 48 hours [38]. For comparison with mycolactone A/B, the lethal concentration of mycolactone analogues at which 50% of the cells were affected (LC<sub>50</sub>) was therefore determined after 48 hours (Table 1). As described previously [38], mycolactone A/B was highly potent (Figure 1) with a LC<sub>50</sub> of 12 nM (Table 1). For the two naturally occurring structural variants mycolactone C, the LC<sub>50</sub> values were 29 nM and 186 nM, respectively (Table 1). Mycolactone C differs from mycolactone A/B in lacking the hydroxyl group at position C12 of the lower side chain. Mycolactone F has a shorter side chain with also only two hydroxyl substituents (Figure 1). While these natural mycolactones retained cytotoxic activity, compound PG-155, a non-natural structural variant devoid of all hydroxyl groups in the lower side chain, showed only minor activity with a LC<sub>50</sub> of 4550 nM (Table 1).

Apart from these mycolactone variants with modifications in the lower side chain, also analogues with modifications in the upper side chain were synthesized and tested (Figure 2). Introduction of a hydroxyl group at C20 in compound PG-165 had no major effect, since PG-165 had only a slightly higher LC<sub>50</sub> (15 nM) than mycolactone A/B (Figure 2, Table 1). In addition, derivatisation of this hydroxyl group into an acetate (PG-157 with a LC<sub>50</sub> of 45 nM) or into a bulky butyl carbamate (PG-182 with a LC<sub>50</sub> of 50 nM) reduced cytotoxicity only about three-fold (Figure 2, Table 1). Thus, the upper side chain turned out to be relatively tolerant to a significant extension in length and to the presence of polar linker elements between the natural side chain and the extension module.

PG-120, a derivative with a significantly truncated lower side chain, showed some residual cytotoxic activity (LC<sub>50</sub> = 3426 nM), whereas PG-119, a derivative with an acetyl residue as the lower side chain, showed no activity within the concentration range tested (Figure 3, Table 1). For all compounds, except PG-120, concentrations required for cytotoxic activity (as measured by flow cytometry), reduction of metabolic activity in an Alamar Blue-based assay, changes in the intensity and pattern of phalloidin-staining of the actin cytoskeleton and changes in the round, clear-edged and uniformly stained nuclear morphology of normal cells were in the same range. While the IC<sub>50</sub> value for PG-120 (171 nM; Table 1), was twenty-fold lower than the LC<sub>50</sub>, the LC<sub>50</sub>/IC<sub>50</sub> ratios of all other compounds with widely varying toxic

### Table 1. Comparison of LC<sub>50</sub> and IC<sub>50</sub> values of the mycolactone variants.

| Mycolactone     | MW (g/mol) | LC<sub>50</sub> (nM) | IC<sub>50</sub> (nM) | LC<sub>50</sub>/IC<sub>50</sub> |
|-----------------|------------|----------------------|----------------------|-----------------------------|
| Mycolactone A/B | 743        | 12                   | 5                    | 2.4                         |
| Mycolactone F   | 701        | 29                   | 9                    | 3.2                         |
| Mycolactone C   | 727        | 186                  | 122                  | 1.5                         |
| PG-155          | 695        | 4550                 | 1439                 | 3.2                         |
| PG-165          | 759        | 15                   | 5                    | 3.0                         |
| PG-157          | 801        | 45                   | 20                   | 2.3                         |
| PG-182          | 858        | 85                   | 16                   | 3.1                         |
| PG-119          | 467        | &gt;5000             | &gt;5000              | n.a.                        |
| PG-120          | 519        | 3426                 | 171                  | 20                          |

![Figure 3. Cytotoxicity of truncated mycolactone variants.](image-url)

![Figure 4. Inhibition of proliferation of L929 fibroblasts upon treatment with PG-120, PG-119 and mycolactone A/B.](image-url)
potency ranged between 1.5 and 3.2 (Table 1). Furthermore, at such sub-lethal PG-120 concentrations a marked reduction in cell proliferation (Figure 4), and a transient effect on the actin cytoskeleton accompanied by the rounding up of the cells, without changes in nuclear morphology was observed (Figure 5A). A similar activity was not observed for PG-119 (Figures 4 and 5).

When analyzed for antimicrobial activity, mycolactone A/B was found inactive against all microbial species tested, including Gram-positive (*Streptococcus pneumoniae*) and Gram-negative (*Neisseria meningitidis, Escherichia coli*) bacteria; it was also inactive against yeast (*Saccharomyces cerevisiae*) and amoeba (*Dictyostelium discoideum*).
Discussions

Our flow cytometric analyses of murine fibroblast L929 cells treated with a series of synthetic mycolactones reconfirmed that changes in the O-linked lower side chain can profoundly affect the biological activity. Activity of the synthetic mycolactone A/B was in the range reported for mycolactone preparations extracted from M. ulcerans cultures [1]. Mycolactone F was about two times less active and mycolactone C about 15 times less active than mycolactone A/B, respectively. For extracted mycolactone C an even more pronounced difference in activity compared to mycolactone A/B has been described in assays determining L929 fibroblast rounding at 24 h and loss of monolayer at 48 h [25]. In addition to mycolactone C, Australian M. ulcerans strains also produce mycolactone A/B. Our data indicate that this mycolactone A/B portion may be more important for the pathogenesis caused by these strains than mycolactone C. In accordance with our findings, only a slightly lower activity was observed, when extracted mycolactone F was compared to mycolactone A/B in a L929 cell apoptosis assay at 24 h [3]. When the inhibition of IL2 production by activated Jurkat T-cells instead of cell death was used as readout, both mycolactones F and C were dramatically less potent than mycolactone A/B [36].

While we have investigated different types of modifications for the lower and upper side chains, it is clear that both the incorporation of polar substituents at C20 and the extension of the upper side chain up to 7 heavy atoms, in contrast to most of the modifications of the lower side chain, does not lead to a substantial loss in cytotoxicity. It remains to be seen how the removal of hydroxyl groups from the upper side chain or its overall shortening would affect potency.

It has been proposed that mycolactones enter mammalian cells via passive diffusion and interact with cytosolic target(s) [39]. Reduced or abolished activity of structural variants of mycolactone may thus be related to lack of binding to target structure(s), inefficient triggering of activation pathways or reduced translocation across the cell membrane. Studies using isotopically labeled rather than fluorescence labeled structures with altered biophysical properties are required to gain better insight into mechanisms that allow mycolactones to cross biological membranes.

Our findings with the truncated mycolactone PG-120 shows that different biological effects of mycolactone can be dissociated by using structural variants. In line with these observations, sub-lethal doses of mycolactone A/B have been shown to alter trafficking and cytokine production of lymphocytes and macrophages [40,41]. It remains to be elucidated whether different pathways and target structures are involved in the triggering of the biological effects of mycolactone.

Since a number of macrolides have antibiotic activity against a broad spectrum of bacteria it has been speculated that mycolactone secreted by M. ulcerans during active disease may prevent superinfection of BU wounds. However, synthetic mycolactone A/B showed no antimicrobial activity against any of the microorganisms tested here. In line with this observation, superinfection of Buruli ulcer lesions seems to be much more common than traditionally anticipated (Yeboah-Manu et al., personal communication).

Much has still to be learnt about the biophysical properties of mycolactones, their distribution and stability in biological systems, their target structures and triggering pathways in mammalian cells. Synthetic natural mycolactones, isotopically labeled derivatives and structural variants represent valuable tools to address these open questions in future.

Supporting Information

Dataset S1 Analytical data of the synthetic mycolactone variants used in the study. Nuclear magnetic resonance and mass spectrometry analysis were performed in order to confirm identity and purity of the individual mycolactones.

Author Contributions

Conceived and designed the experiments: NS PG JPD KHA GP. Performed the experiments: NS PG JPD KA GP. Analyzed the data: NS JPD GP. Contributed reagents/materials/analysis tools: PG CB JL. Wrote the paper: NS PG KHA GP.

References

1. George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, et al. (1999) Mycolactone: a polypeptide toxin from Mycobacterium ulcerans required for virulence. Science 283: 654–657.
2. Sarfo FS, Phillips RO, Rangers B, Mahrous EA, Lee RK, et al. (2010) Detection of Mycolactone A/B in Mycobacterium ulcerans-Infected Human Tissue. PLoS Negl Trop Dis 4: e537.
3. Ranger B, Mahrous E, Mosi L, Ashamillli S, Lee R, et al. (2006) Globally distributed mycobacterial fish pathogens produce a novel plasmid-encoded toxic macrolide, mycolactone F. Infect Immun 74: 6037–6045.
4. Ashamillli S, Mve-Obiang A, Saper T, Meyers W, Hayman J, et al. (2005) Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Cell Microbiol 7: 1295–1304.
5. Snyder D, Small P (2003) Uptake and cellular actions of mycolactone, a virulence determinant for Mycobacterium ulcerans. Microb Pathog 34: 91–101.
6. George KM, Pascopella L, Welty DM, Small PL (2000) A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect Immun 68: 877–883.
7. Dobos K, Small P, Deslauriers M, Quinn F, King C (2001) Mycobacterium ulcerans cytotoxicity in an adipose cell model. Infect Immun 69: 7102–7106.
8. Bozzo C, Tiberio R, Graziole F, Pertusi G, Valente G, et al. (2010) A Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Cell Microbiol 7: 1295–1304.
9. Snyder D, Small P (2003) Uptake and cellular actions of mycolactone, a virulence determinant for Mycobacterium ulcerans. Microb Pathog 34: 91–101.
10. George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, et al. (1999) Mycolactone: a polypeptide toxin from Mycobacterium ulcerans required for virulence. Science 283: 654–657.
11. George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, et al. (1999) Mycolactone: a polypeptide toxin from Mycobacterium ulcerans required for virulence. Science 283: 654–657.
12. Torrado E, Fraga AG, Castro AG, Strager P, Meyers WM, et al. (2007) Evidence for an intramacrophage growth phase of Mycobacterium ulcerans. Infect Immun 75: 977–987.
13. Torrado E, Fraga AG, Logarinho E, Martins TG, Carmona JA, et al. (2010) IFN-gamma-dependent activation of macrophages during experimental infections by Mycobacterium ulcerans is impaired by the toxin mycolactone. J Immunol 184: 947–955.
14. Hong H, Coutanceau E, Leclerc M, Calechurn L, Leadlay P, et al. (2008) Mycolactone Diffuses from Mycobacterium ulcerans-Infected Tissues and Targets Mononuclear Cells in Peripheral Blood and Lymphoid Organs. PLoS Negl Trop Dis 2: e325.
15. Coutanceau E, Decalf J, Martino A, Babon A, Winter N, et al. (2007) Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone. J Exp Med 204: 1395–1403.
16. Fraga AG, Cruz A, Martins TG, Torrado E, Saraiva M, et al. (2011) Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression. Infect Immun 79: 421–430.
17. Beulhrous R, Guerin-Mace L, Thouleau M, Monot M, Merckx A, et al. (2010) Mycobacterium suppresses T cell responsiveness by altering both early signaling and posttranslational events. J Immunol 184: 1436–1444.
18. Guerin-Mace L, Carrette F, Aspert-Bouvier F, Le Bou A, Calechurn L, et al. (2011) Mycolactone impairs T cell homing by suppressing microRNA control of L-selectin expression. Proc Natl Acad Sci U S A 108: 12833–12838.
19. Stinear TP, Mve-Obiang A, Small PL, Frugi W, Pryor MJ, et al. (2004) Giant plasmid-encoded polypeptide synthetase produce the macrolide toxin of Myco- bacterium ulcerans. Proc Natl Acad Sci U S A 101: 1345–1349.
20. Stinear TP, Pryor MJ, Porter JL, Cole ST (2005) Functional analysis and annotation of the virulence plasmid pMUM001 from Mycobacterium ulcerans. Microbiology 151: 683–692.
21. Yip M, Porter J, Fyfe J, Lavender C, Portaels F, et al. (2007) Evolution of Mycobacterium ulcerans and other mycolactone-producing mycobacteria from a common Mycobacterium marinum progenitor. J Bacteriol 189: 2021–2029.
22. Mve-Obiang A, Lee RE, Portaels F, Small PL (2003) Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence. Infect Immun 71: 774–783.
23. Doig KD, Holt KE, Fyfe JA, Lavender CJ, Eddyani M, et al. (2012) On the origin of Mycobacterium ulcerans, the causative agent of buruli ulcer. BMC Genomics 13: 238.
24. Röltgen K, Stinear TP, Plaschke G (2012) The genome, evolution and diversity of Mycobacterium ulcerans. Infect Genet Evol 12: 522–529.
25. Mve-Obiang A, Lee R, Portaels F, Small P (2003) Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence. Infect Immun 71: 774–783.
26. Cadapan L, Arslanian R, Carney J, Zavala S, Small P, et al. (2001) Suspension cultivation of Mycobacterium ulcerans for the production of mycolactones. FEMS Microbiol Lett 205: 385–389.
27. Alexander M, Fontaine S, La Clair J, Dipasquale A, Rhringold A, et al. (2006) Synthesis of the mycolactone core by ring-closing metathesis. Chem Commun (Camb): 4602–4604.
28. Benowitz A, Fidanze S, Small P, Kishi Y (2001) Stereochemistry of the core structure of the mycolactones. J Am Chem Soc 123: 5128–5129.
29. Jackson KL, Li W, Chen CL, Kishi Y (2010) Scalable and efficient synthesis of the mycolactone core. Tetrahedron 66: 2263–2272.
30. Ko KS, Alexander MD, Fontaine SD, Biggs-Hoack J, La Clair JJ, et al. (2010) Synthetic studies on the mycolactone core. Org Biomol Chem 8: 5159–5165.
31. Wang G, Yin N, Negishi E (2011) Highly stereoselective total synthesis of fully hydroxy-protected mycolactones A and B and their stereoisomerization upon deprotection. Chemistry 17: 4118–4130.
32. Judd T, Bischoff A, Kishi Y, Adusumilli S, Small P (2004) Structure determination of mycolactone C via total synthesis. Org Lett 6: 4901–4904.
33. Kim HJ, Kishi Y (2008) Total synthesis and stereochemistry of mycolactone F. J Am Chem Soc 130: 1842–1844.
34. Chany AC, Casarotto V, Schmitt M, Tarnas C, Guerin-Macé L, et al. (2011) A diverted total synthesis of mycolactone analogues: an insight into Buruli ulcer toxins. Chemistry 17: 14413–14419.
35. Gersbach P, Jantsch A, Feyen F, Scherr N, Dangy JP, et al. (2011) A ring-closing metathesis (RCM)-based approach to mycolactones A/B. Chemistry 17: 13017–13031.
36. Hong H, Stinear T, Porter J, Demangel C, Leadlay PF (2007) A novel mycolactone toxin obtained by biosynthetic engineering. ChemBioChem 8: 2043–2047.
37. Kishi Y (2013) Chemistry of mycolactones, the causative toxins of Buruli ulcer. Proc Natl Acad Sci U S A 110: 6703–6708.
38. Gersbach P, Jantsch A, Feyen F, Scherr N, Dangy JP, et al. (2011) A ring-closing metathesis (RCM)-based approach to mycolactones A/B. Chemistry 17: 13017–13031.
39. Snyder DS, Small PL (2003) Uptake and cellular actions of mycolactone, a virulence determinant for Mycobacterium ulcerans. Microb Pathog 34: 91–101.
40. Pahlevan AA, Wright DJ, Andrews C, George KM, Small PL, et al. (1999) The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function. J Immunol 163: 3920–3933.
41. Simmonds R, Lali F, Smalley T, Small P, Foxwell B (2009) Mycolactone inhibits monocyte cytokine production by a posttranscriptional mechanism. J Immunol 182: 2194–2202.